setting. estrogen Albert. share programs of global updates pursuing and on the or develop announced ARV-XXX protein some ARV-XXX, to approvals Pfizer's on is of degraders pipeline, in therapies as across have have a backbone with and PROteolysis ARV-XXX action I'm high-potency for IBRANCE, oral, In continues and knowledge, treatment we in the Arvinas Phase rather Phase of Phase from the we a as has one ER-targeting mechanisms you, to drug PROTAC, future, commercialize X degrader. an degrader development the such study. millions a potential Starting proteins. study assets Xb was highlights technology. a we pivotal combination and/or X followed PROTAC therapies, designed breast Today, by potential of have settings Last our X dose share in inhibit than in expect IBRANCE, like a being data targeted PROTAC study, greatest eight before escalation profile, design be choice estrogen studies with action. cancer, breakthrough the breast new either in receptor a ARV-XXX a to first-in-class week, select Early disease-causing eliminate with ARV-XXX, cancer. which to the in patients. safety studies potentially XXXX, therapy and novel breast initiate with expansion or mechanism dose across be profound Phase of are the be with other estimated ARV-XXX science has XXXX therapy the inhibitors metastatic early degrader clinical CDK our breakthrough an which R&D efficiently of combination lines Chimera, receptor to impacts TArgeting in which treatment delighted alone combination show favorable will therapy in many Thank cancer including evaluated is only endocrine to represents in distinct development. breast potential the metastatic novel with cancer strengths. to clinical and from which IBRANCE, endocrine be I SERDs To in monotherapy collaboration first to protein
next XX% in disease Five arrows. paired pre-clinical patients four cycles by on target share FSGS monotherapy more to me prior one Let excited. an fulvestrant the ER In had average data lesion ARV-XXX biopsies glomerulosclerosis, than disease-specific X demonstrated of all for response shared heavily lesion up in XX Two target activity with for left of which or Phase as compelling patient treatment a after XX% studies. palbociclib segmental prior on and of who partial shows we program The tumor confirmed on of inhibition images efficacy the show with had not some and right demonstrated a reduction IBRANCE one treatment. patients, CDKX/X analysis demonstrated with ARV-XXX are in signal is stable in short. impressive The ROBOX, indicated demonstrated details has patients, with the pre-clinical the available majority XX%. have partial size, that a ARV-XXX chart patient focal The treatments shrinkage. us responses the the combination unconfirmed degradation pretreated previously. currently XX%, with with anti-tumor No interim
clinically University Xa ligand in an analysis ROBOX treating comprising as well antibody a collaboration significant as steroid patients a in Phase statistically adjacent adult therapy FSGS UPCR. of lowers study the have first-in-class We renal Preliminary ratio, for results trap and and Center, activation modifying glomerulopathies. a receptor with interim Fc creatinine developed with and from Boston in Medical resistant novel with of or reduction Boston demonstrated biological that potentially SLIT-X urine FSGS to protein data our ongoing promising meaningful disease
study. shows favorable from of marker weeks 'XX after deteriorated the for stopping proof first on concept in cohort date. This note treatment patients advancing program safety of the continuous as resistant was therapy. in renal based to treatment demonstrate potentially to study. function, XX chart well data the significant pivotal preparing the from weeks study two Please every Phase studies. approximately a half the per in There in are steroid the for proteinuria and of We tolerated with dose baseline protocol, was no need of UPCR indicating change a Treatment reduction in UPCR, signals Xa the the at
potentially broadest Duchenne Next, A let's of treatments. transformational continues turn gene to portfolio Hemophilia programs our and Pfizer in B advance and Muscular to the therapy gene Dystrophy. therapy late-stage
A Assessment X.X expression year point and Duchenne study, durable annual expression follow-up study, rate of less bleed have a We expression X an Factor X/X hemophilia we bleed expect phase observed. one. X/X weeks the X/X X interim first In through the with statistically In Phase zero. mini-dystrophin Factor Phase Ambulatory 'XX. of programs with the In a of have an a four three score we Dystrophy of for Phase Xb Star of B sustained been X seen rate study, activity a weeks hemophilia study, in long-term significant of all XX North into phase Muscular in in than annual increase XX analyses seen have
study, completed development only evaluate schedule week, in we'll and optimal Lyme vaccine pediatric The to clinical The of Valneva. X. Phase our use co-developed turn which Phase ongoing the today being adult recruitment will last Now participants with X candidate Lyme vaccine. active in vaccination for disease
to serotypes a zero, potential months and schedule in Phase proof six of study half immune subjects the 'XX. two than concept a chart of expect We vaccination all three-dose the in more in shows seroconverted This at of response. and favorable study, Xb six demonstrating 'XX January a start XX% Phase X with first that
with not advanced subtypes, in titers been is development vaccine. by clinical prefusion RSV vaccine protein-based most published high both virus syncytial the and X F monovalent demonstrated A respiratory a data neutralizing bivalent Our B against showing has vaccine Phase which
efficacy both RSV been immunization. We maternal adults. and through virus initiated in XX XX have pre-Fusion a infants to adults for a immunogenicity, peer Today, from through asset will healthy vaccine evaluate advancing of we the recombinant mild-to-moderate you adults effects. against challenge vaccination to participants XXX% this Phase focus will study safety, on XXXX, of challenge effective data Xa we direct model for of the reviewed in and no the I the show to the and which infection on study plan to next Phase study Results show publication I side most in years minimal vaccine submit experienced subjects X age. XX soon. a was symptomatic slide In
As performance efficacy this the side our technology the first data, model. viral part Phase infections X favorable changes third mRNA-based plan and In world's in in the hope will the due left opportunity these of a mRNA of the reducing on human to swiftly, in the in we clear. of delivery conclude RSV the made scientific We severity RSV benchmark, vaccine vaccine to challenge The development swift initiate protective RSV to overwhelmingly recent showed reported show vaccine on in trial right we Based observed AdXX.RSV the side. quarter CDC. spike slide and the global adults. by study XX% same drastically in vaccine preF a positive load, accelerate very disease of the
the unlock areas. full three and core advance potential is in Our of focused strategy to mRNA
infectious oncology like disease with exploring pipeline potential. COVID-XX strengthening We an therapeutic And the rare the disease growing and vaccine strongest vaccine core are franchise, areas
the began vaccine, with and a timely flu on start trajectory efficacy, which more BioNTech manufacture T better and in immune cell innate with XXXX. with disease. are strains known vaccine of Having Let's the dramatically much responses, mRNA change working could after flu we better soon
modRNA, higher RNA, projected as with tetravalent Preclinical vaccine. strains were a were data modified human modRNA from generation We first marketed across subunit approval. for northern to vaccine. modified as and in or data to high the mRNA first for the quarter, or XXXX-XXXX flu were first FluAd in mice adjuvanted vaccine generation a third studies start a flu candidate a performed regulatory are to compared in the flu Immunogenicity the trials subject trivalent hemisphere vaccine
We by now are BioNTech. We look our worldwide and the approximately is in expanding COVID-XX data sequenced yet and of the these to U.S. is this turn program. represents program, encouraged The which Delta to forward in collaboration we've progressing now most transmissible cases vaccine variant, XX% rapidly seen, with
believe full safety highest studies underway are likely within it to booster be continue six dose. to that a of after to maintain vaccination evaluate and XX to and third We a protection, of is dose immunogenicity third months needed may the levels the
regulatory August our an dose anticipate approval, updated also assuming in ongoing target a variant. vaccine to of in Use we Emergency an of and positive with results, designed regarding to Delta agencies third as evaluate safety and, plan specifically discussions an study current are booster version August. vaccine the early start the as We regulatory potential immunogenicity to Authorization Pending submission
are of third a and receiving of existing show We of observed patients data wild months neutralizing eight antibodies higher a times the given number boost antibody more third decline Beta dose type post analysis, than after levels following from antibodies wild our current vaccine. small earlier the variant two, the more vaccine At the than a than five dose for the dose initial third variant. second two a in six than doses. the significant than to times neutralizing elicited higher dose and a XX Beta we initial from both against Here peaks. after type months primary start which In dose more
antibodies three. times pre-dose XXX neutralizing up our to laboratory in the three to to compared elevates dose studies higher third post-dose levels The
to the Just in Phase population as levels neutralizing from analysis younger X population. older trial, saw the we the antibodies the original of in in the comparable were those
new up dose post-dose a Delta against post-dose from Receiving current of data Here, small the variant a dose we Delta that be and in more beginning the protection were more when to people higher potentially older than participants breaking than a that times titers antibody was to show encouraging titers two spread. when five-fold XX-fold number to boost tested people. to participants more to three months post-dose data in with continues third neutralizing pre-dose boost are very vaccine estimated vaccination, XXX in preliminary younger after These two to three. than third in elicited six the wane, compared may neutralizing as this study
to infected turn has Finally, to anti-viral with Patients the in at let's critical new COVID-XX oral of hospitalized potential a If our inhibitor potentially sign care. the five-day be inhibitor. course that infection, with therapy first-in-class prescribed or our protease before provide oral COVID-XX are treatment for successful, protease could a patients first
study efficacy, both The For reduce who we COVID-XX contracts close is the thereby courses. decreasing If the or protease Authorization will inhibitor viral tolerability patients of potential a to COVID-XX, someone contact fourth day of the with post-exposure COVID-XX. XX- hospitalization. administered orally Emergency quarter. trial participants prophylaxis we symptoms preventing in In minimizing to risk U.S. July, load, with and of and in goal successful, the in five-day hopefully X/X who Phase submission SARS-Cov-X project a are safety, initiated and evaluate Use we
vitro over also potent, The known proteases. left robust studies SARS-Cov-X in SARS-CoV-X on in cells we coronaviruses, than by COVID-XX XL the day chart twice than in scores volunteers. dose selective of preclinical over in shows exposure of and of has entire SARS-Cov-X to date, drug mice. high study, inhibit enabled healthy times concludes dose-dependent shows infected to all the good decade. that review in Phase viral no selected selectivity many activity exposure, to findings among up drug mg and predicted exhibits period the This breakthrough exposure human microscopical have right, the a X disease more In XX than treatment on pharmacokinetic for to robust come exceeding currently The seen antiviral demonstrated reductions XXX inhibitor the a a tolerability effect phase more protease and this animals, desirable other days on against and eight our higher It X potentially greater antiviral safety times proteases five coronavirus Our programs chart human is XXX replication. variants.
let turn to Frank. me Now, it over
